Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 10 |
| List of Tables | 10 | 1 |
| List of Figures | 11 | 1 |
| Introduction | 12 | 1 |
| Global Markets Direct Report Coverage | 12 | 1 |
| Pulmonary Arterial Hypertension Overview | 13 | 1 |
| Therapeutics Development | 14 | 2 |
| Pipeline Products for Pulmonary Arterial Hypertension Overview | 14 | 1 |
| Pipeline Products for Pulmonary Arterial Hypertension Comparative Analysis | 15 | 1 |
| Pulmonary Arterial Hypertension Therapeutics under Development by Companies | 16 | 3 |
| Pulmonary Arterial Hypertension Therapeutics under Investigation by Universities/Institutes | 19 | 1 |
| Pulmonary Arterial Hypertension Pipeline Products Glance | 20 | 3 |
| Late Stage Products | 20 | 1 |
| Clinical Stage Products | 21 | 1 |
| Early Stage Products | 22 | 1 |
| Pulmonary Arterial Hypertension Products under Development by Companies | 23 | 4 |
| Pulmonary Arterial Hypertension Products under Investigation by Universities/Institutes | 27 | 1 |
| Pulmonary Arterial Hypertension Companies Involved in Therapeutics Development | 28 | 39 |
| Actelion Ltd | 28 | 1 |
| APT Therapeutics, Inc. | 29 | 1 |
| Arena Pharmaceuticals, Inc. | 30 | 1 |
| Ascendis Pharma A/S | 31 | 1 |
| AVEO Pharmaceuticals, Inc. | 32 | 1 |
| Bial - Portela &Ca, S.A. | 33 | 1 |
| Celsion Corporation | 34 | 1 |
| Celtaxsys, Inc. | 35 | 1 |
| Chugai Pharmaceutical Co., Ltd. | 36 | 1 |
| Complexa, Inc. | 37 | 1 |
| Eli Lilly and Company | 38 | 1 |
| Galectin Therapeutics, Inc. | 39 | 1 |
| Gilead Sciences, Inc. | 40 | 1 |
| Hanmi Pharmaceuticals, Co. Ltd. | 41 | 1 |
| HitGen LTD | 42 | 1 |
| Insmed Incorporated | 43 | 1 |
| INVENT Pharmaceuticals, Inc. | 44 | 1 |
| Johnson &Johnson | 45 | 1 |
| Kowa Company, Ltd. | 46 | 1 |
| Mast Therapeutics, Inc. | 47 | 1 |
| Mezzion Pharma Co. Ltd. | 48 | 1 |
| miRagen Therapeutics, Inc. | 49 | 1 |
| Morphogen-IX Limited | 50 | 1 |
| Nippon Kayaku Co., Ltd. | 51 | 1 |
| Nippon Shinyaku Co., Ltd. | 52 | 1 |
| Novartis AG | 53 | 1 |
| Peloton Therapeutics, Inc. | 54 | 1 |
| PhaseBio Pharmaceuticals, Inc. | 55 | 1 |
| Pluristem Therapeutics Inc. | 56 | 1 |
| Proteo, Inc. | 57 | 1 |
| Pulmokine, Inc. | 58 | 1 |
| Reata Pharmaceuticals, Inc. | 59 | 1 |
| Respira Therapeutics, Inc. | 60 | 1 |
| Reviva Pharmaceuticals Inc. | 61 | 1 |
| Selten Pharma, Inc | 62 | 1 |
| Silence Therapeutics Plc | 63 | 1 |
| SteadyMed Therapeutics, Inc. | 64 | 1 |
| Suda Ltd | 65 | 1 |
| Toray Industries, Inc. | 66 | 1 |
| Pulmonary Arterial Hypertension Therapeutics Assessment | 67 | 13 |
| Assessment by Monotherapy Products | 67 | 1 |
| Assessment by Target | 68 | 4 |
| Assessment by Mechanism of Action | 72 | 4 |
| Assessment by Route of Administration | 76 | 2 |
| Assessment by Molecule Type | 78 | 2 |
| Drug Profiles | 80 | 118 |
| acebilustat Drug Profile | 80 | 3 |
| Antibody for Pulmonary Arterial Hypertension Drug Profile | 83 | 1 |
| Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension Drug Profile | 84 | 1 |
| APT-602 Drug Profile | 85 | 1 |
| AV-353 Drug Profile | 86 | 1 |
| bardoxolone methyl Drug Profile | 87 | 4 |
| beraprost sodium ER Drug Profile | 91 | 1 |
| beraprost sodium SR Drug Profile | 92 | 1 |
| BIA-51058 Drug Profile | 93 | 1 |
| BMP-10 Drug Profile | 94 | 1 |
| BMP-9 Drug Profile | 95 | 1 |
| CTX-3397 Drug Profile | 96 | 1 |
| CXA-10 Drug Profile | 97 | 2 |
| Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension Drug Profile | 99 | 1 |
| GMA-301 Drug Profile | 100 | 1 |
| GMCT-01 Drug Profile | 101 | 4 |
| GRMD-02 Drug Profile | 105 | 11 |
| HGP-1207 Drug Profile | 116 | 1 |
| INS-1009 Drug Profile | 117 | 2 |
| INV-240 Drug Profile | 119 | 1 |
| JNJ-26993135 Drug Profile | 120 | 1 |
| KAR-5585 Drug Profile | 121 | 1 |
| macitentan Drug Profile | 122 | 5 |
| MFC-1040 Drug Profile | 127 | 1 |
| MFC-2040 Drug Profile | 128 | 1 |
| Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases Drug Profile | 129 | 1 |
| Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension Drug Profile | 130 | 1 |
| PB-1046 Drug Profile | 131 | 2 |
| PB-1120 Drug Profile | 133 | 1 |
| PF-543 Drug Profile | 134 | 1 |
| pitavastatin NP Drug Profile | 135 | 1 |
| PK-10453 Drug Profile | 136 | 1 |
| PK-10571 Drug Profile | 137 | 1 |
| PLX-PAD Drug Profile | 138 | 8 |
| PT-2977 Drug Profile | 146 | 1 |
| QCC-374 Drug Profile | 147 | 1 |
| R-190 Drug Profile | 148 | 2 |
| ralinepag Drug Profile | 150 | 2 |
| RP-5063 Drug Profile | 152 | 2 |
| RT-234 Drug Profile | 154 | 1 |
| selexipag Drug Profile | 155 | 4 |
| selonsertib Drug Profile | 159 | 1 |
| sirolimus albumin-bound Drug Profile | 160 | 2 |
| Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology and Oncology Drug Profile | 162 | 1 |
| Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension Drug Profile | 163 | 1 |
| Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension Drug Profile | 164 | 1 |
| Small Molecules to Antagonize PDGFR for Pulmonary Arterial Hypertension Drug Profile | 165 | 1 |
| Small Molecules to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension Drug Profile | 166 | 1 |
| sodium nitrite Drug Profile | 167 | 3 |
| SPI-054 Drug Profile | 170 | 1 |
| SPI-183 Drug Profile | 171 | 1 |
| SUD-004 Drug Profile | 172 | 1 |
| Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension Drug Profile | 173 | 1 |
| tacrolimus Drug Profile | 174 | 1 |
| tadalafil Drug Profile | 175 | 2 |
| tiprelestat Drug Profile | 177 | 4 |
| tocilizumab Drug Profile | 181 | 8 |
| TR-422 Drug Profile | 189 | 1 |
| treprostinil Drug Profile | 190 | 1 |
| treprostinil diolamine Drug Profile | 191 | 2 |
| ubenimex Drug Profile | 193 | 2 |
| udenafil Drug Profile | 195 | 3 |
| Pulmonary Arterial Hypertension Dormant Projects | 198 | 4 |
| Pulmonary Arterial Hypertension Discontinued Products | 202 | 1 |
| Pulmonary Arterial Hypertension Product Development Milestones | 203 | 10 |
| Featured News &Press Releases | 203 | 1 |
| Sep 01, 2016: SteadyMed Announces Completion of Pre-NDA Submission Manufacturing Activities | 203 | 1 |
| Aug 31, 2016: ACTEMRA Subcutaneous Injection Wins a Prize at the JAPAN PACKAGING CONTEST 2016 | 203 | 1 |
| Aug 17, 2016: Karos Pharmaceuticals Announces Major Milestone Events | 204 | 1 |
| Aug 16, 2016: Actelion Receives Swissmedic Approval For Uptravi (Selexipag) For Treatment Of Pulmonary Arterial Hypertension | 204 | 1 |
| Jul 18, 2016: Cialis now available at a lower price | 205 | 1 |
| Jul 18, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension | 205 | 1 |
| Jun 23, 2016: Reata Pharmaceuticals Announces Interim Data From Extension Phase 2 LARIAT Study in Pulmonary Arterial Hypertension | 206 | 1 |
| Jun 15, 2016: Actelion Announces Commercial Availability Of Uptravi (Selexipag) In Germany | 206 | 1 |
| Jun 02, 2016: Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial Hypertension | 207 | 1 |
| May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016 | 208 | 1 |
| May 17, 2016: Actelion is granted marketing authorization for Uptravi (selexipag) in pulmonary arterial hypertension by the European Commission | 208 | 2 |
| May 05, 2016: Preclinical Research on the Role of Galectin-3 in Pulmonary Arterial Hypertension to be Presented at the American Thoracic Society 2016 International Conference | 210 | 1 |
| May 02, 2016: AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAH | 210 | 1 |
| Apr 25, 2016: Steadymed Announces Public Availability Of Ptab Decision To Institute Inter Partes Review Proceedings | 211 | 1 |
| Apr 14, 2016: Steadymed To Host An Analyst And Investor Reception | 212 | 1 |
| Appendix | 213 | 2 |
| Methodology | 213 | 1 |
| Coverage | 213 | 1 |
| Secondary Research | 213 | 1 |
| Primary Research | 213 | 1 |
| Expert Panel Validation | 213 | 1 |
| Contact Us | 213 | 1 |
| Disclaimer | 214 | 1 |